·知识介绍·

许颖, 李哲, 龚冬梅, 班涛, 孙桂元, 白云龙

中国药学杂志 ›› 2015, Vol. 50 ›› Issue (11) : 921-924.

PDF(700 KB)
中国药学杂志
PDF(700 KB)
中国药学杂志 ›› 2015, Vol. 50 ›› Issue (11) : 921-924. DOI: 10.11669/cpj.2015.11.001
·综 述·

·知识介绍·

  • 许颖, 李哲, 龚冬梅, 班涛, 孙桂元, 白云龙
作者信息 +

Rescent Progress in Research on Prevention Strategy for Toxicity of Arsenic Trioxide Injection

  • XU Ying, LI Zhe,GONG Dong-mei,BAN Tao,SUN Gui-yuan, BAI Yun-long
Author information +
文章历史 +

摘要

砷是众所周知的一类致癌源,能诱发多种癌症,但其衍生物三氧化二砷(arsenic trioxide,As2O3)却是一种很有潜力的抗癌物,对于急性早幼粒白血病(acute promyelocytic leukemia,APL)等多种肿瘤均具有良好的治疗效果。但As2O3毒性反应较强,这使其临床应用受到限制。因此,预防As2O3在治疗过程中产生的毒副作用越来越得到重视。目前有研究显示可通过改良给药方式、与其他药物联合应用、更新药物剂型等方式来降低其不良反应发生。笔者结合国内外相关文献就防治As2O3毒副作用的实验和临床进展作一综述。

Abstract

It is well known that arsenic is a kind of carcinogen which can induce a variety of cancers.Nevertheless, arsenic trioxide,one of its derivatives,served as a very promising anti-cancer agent, which has a significant effect on acute promyelocytic leukemia and a variety of tumors.However, the severe toxicity of arsenic trioxidel imited its clinical application. Therefore, more attentions have been paid on how to attenuate the side effect during arsenic trioxide treatment.Now, there are some solutions about this problem such as a good administration, drug combination, a suitable formulations, etc.This paper reviewed the laboratory and clinical research on the prevention of the toxicity of arsenic trioxidy.

关键词

三氧化二砷 / 不良反应 / 长QT间期综合征

Key words

arsenic trioxide / adverse reaction / long QT syndrome

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
许颖, 李哲, 龚冬梅, 班涛, 孙桂元, 白云龙. ·知识介绍·[J]. 中国药学杂志, 2015, 50(11): 921-924 https://doi.org/10.11669/cpj.2015.11.001
XU Ying, LI Zhe,GONG Dong-mei,BAN Tao,SUN Gui-yuan, BAI Yun-long. Rescent Progress in Research on Prevention Strategy for Toxicity of Arsenic Trioxide Injection[J]. Chinese Pharmaceutical Journal, 2015, 50(11): 921-924 https://doi.org/10.11669/cpj.2015.11.001
中图分类号： R979.1   

参考文献

[1] ZHANG T D,LI S Y. Ai ling No. 1--clinical analysis and experimental research. Chin J Integr Tradit West Med(中西医结合杂志),1984,4(1): 19-20.
[2] CUI Y H, LIANG H J, ZHANG Q Q, et al. Radiosensitivity enhancement by arsenic trioxide in conjunction with hyperthermia in the EC-1 esophageal carcinoma cell line. Asian Pac J Cancer Prev,2012, 13(4): 1693-1697.
[3] WANG H, GAO P, ZHENG J. Arsenic trioxide inhibits cell proliferation and human papillomavirus oncogene expression in cervical cancer cells. Biochem Biophys Res Commun,2014, 451(4): 556-561.
[4] YANG M H, ZANG Y S, HUANG H, et al. Arsenic trioxide exerts anti-lung cancer activity by inhibiting angiogenesis. Curr Cancer Drug Targets, 2014,14(6): 557-566.
[5] MENG Y L, HU H T, LI H L, et al. The clinical therapeutic effects of arsenic trioxide combined with transcatheter arterial chemoembolization in treating primary liver cancer with pulmonary metastases . Chin J Intern Med(中华内科杂志), 2012,51(12): 971-974.
[6] PETTERSSON H M, PIETRAS A, MUNKSGAARD P M, et al. Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells. Mol Cancer Ther,2009, 8(1): 160-170.
[7] MA Y, WANG J, LIU L, et al. Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: Role of Akt and nuclear factor-kappaB. Cancer Lett,2011,301(1): 75-84.
[8] ROBOZ G J, RITCHIE E K, CARLIN R F, et al. Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide. J Clin Oncol,2014,32(33): 3723-3728.
[9] MATHEWS V V, PAUL M V, ABHILASH M, et al. Myocardial toxicity of acute promyelocyticleukaemia drug-arsenic trioxide. Eur Rev Med Pharmacol Sci,2013,17(Suppl 1): 34-38.
GAO N N, ZHOU J. Analysis of therapeutic effect of arsenic trioxide continued slow intravenous injection. Chin J Clinician,2012,6(6): 8-10.
ZHOU J.Arsenic trioxide an ancient drug revived. Chin Med J (Engl),2012,125(19): 3556-3560.
AGGARWAL BB, BHARDWAJ A, AGGARWAL RS, et al. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res,2004,24(5A): 2783-2784.
ZHANG J Y,JIANG H,JIANG W M, et al. The study of protective effect of resveratrol on As2O3-induced cardiotoxicity . Her Med(药学导报),2013,10(24): 4-8.
ZHANG W Q, GUO C M, GAO R F,et al. The Protective Role of Resveratrol against Arsenic Trioxide-Induced Cardiotoxicity. Evid Based Complement Alternat Med,Hindwai Publishing cerporation,2013,http://www.hindawi.com/journals/ecam/2013/407839/.
SUN H L,JIAO J D,CHU W F,et al. Verapamil modulating arsenic trioxide-induced QT interval rolongation in guinea pig. J Harbin Med Univ(哈尔滨医科大学学报),2005,39(4):348.
ZHANG W, LIU Y, GE M, et al. Protective effect of resveratrol on arsenic trioxide-induced nephrotoxicity in rats. Nutr Res Pract,2014,8(2): 220-226.
ZHANG W, XUE J, GE M, YU M, LIU L, ZHANG Z. Resveratrol attenuates hepatotoxicity of rats exposed to arsenic trioxide. Food Chem Toxicol,2013, 51: 87-92.
YANG B F, JI X M, JIA J P. Peripheral vein 20% mannitol bolus to help through the arsenic trioxide to prevent CNS leukemia research.The first part of mannitol intravenous injection of temporary noninvasive blood brain barrier opening for the treatment of central nervous system leukemia of . Tenth National Experimental Hematology Meeting,2005:392-393.
ZHOU J, MENG R, LI M, et al. Protective Effect of Ganglioside on Human Cortical Neuron Treated by Arsenic Trioxide. Chin Pharm J(中国药学杂志),2006, 41(1): 29-33.
CHEN X, SHAN H, ZHAO J, et al. L-type calcium current (ICa,L) and inward rectifier potassium current (IK1) are involved in QT prolongation induced by arsenic trioxide in rat. Cell Physiol Biochem,2010, 26(6): 967-974.
DROLET B, SIMARD C, RODEN D M. Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation,2004, 109(1): 26-29.
DONG D L, SONG W H, PEI L, YANG B F. Arsenic trioxide-induced hela cell death is partially prevented by K+ channel blockers. Acta Pharm Sin(药学学报),2005,40(7): 644-648.
ZHAOX,ZHANGKP,HUANGT,et al. The rescuable function andmechanism of resveratrol on As2O3-induced hERG K+ channel deficiency . Naunyn-Schmiedeberg's Arch Pharmacol,2014,387:1079-1089.
SHEIKH A, YEASMIN F, AGARWAL S, et al. Protective effects of Moringaoleifera Lam. leaves against arsenic-induced toxicity in mice. Asian Pac J Trop Biomed,2014,4(1): 353-358.
PAL S, CHATTERJIE A K. Prospective protective role of melatonin against arsenic-induced metabolic toxicity in Wistarrats. Toxicology, 2005,208(1): 25-33.
KUMAZAKI M, ANDO H, SASAKI A, et al. Protective effect of alpha-lipoic acid against arsenic trioxide-induced acute cardiac toxicity in rats. J Pharmacol Sci, 2011,115(2): 244-248.
AHN R W, BARRET S L, RAJA M R, et al. Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo. PLoS One, 2013,8(3): e58491.
MA M L, GUO M H, YANG L J, et al. Development of new dosage form of arsenic trioxide. Chin Pharm J(中国药学杂志),2011,46(7): 489-492.
ZHU H H, QIN Y Z, HUANG X J. Resistance to arsenic therapy in acute promyelocyticleukemia. N Engl J Med,2014,370(19): 1864-1866.
SHAN H, ZHANG Y, CAI B, et al. Upregulation of microRNA-1 and microRNA-133 contributes to arsenic-induced cardiac electrical remodeling. Int J Cardiol, 2013,167(6): 2798-2805.

基金

黑龙江省教育厅科学技术研究资助项目(12511317)
PDF(700 KB)

94

Accesses

0

Citation

Detail
段落导航
相关文章

/

〈 〉